|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.00 - 32.00|
|52 Week Range||19.50 - 32.43|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||16.84|
|Forward Dividend & Yield||0.99 (3.11%)|
|Ex-Dividend Date||May 18, 2023|
|1y Target Est||N/A|
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Most readers would already be aware that Fresenius SE KGaA's (ETR:FRE) stock increased significantly by 20% over the...
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price. Fresenius joins drugmakers Boehringer Ingelheim, Sandoz and Organon, which launched Humira biosimilars, or copies of biologic drugs, this week. Industry experts have said that most new biosimilars are expected to debut with marginal discounts to Humira's monthly price of $6,922.